Elos Medtech (ELOS-B.ST) Stock Analysis & AI Equity Report
Elos Medtech (ELOS-B.ST) overview
Elos Medtech (ELOS-B.ST) stock analysis and AI equity research. For the latest completed financial year, 2022, Elos Medtech reported revenue of SEK 889m and operating profit of SEK 122m; the year-end share price was 246.00 SEK and market capitalisation was SEK 1,985m. Elos Medtech is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Elos Medtech's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Elos Medtech
Elos Medtech develops and manufactures medical technology products and components for customers in dental, orthopedics, advanced surgical and precision applications. The company provides product development, prototyping, testing, regulatory support, process optimization, packaging and contract manufacturing services, with additional expertise in dental implants and instruments, orthopedic components and other medical device solutions.
Generate the Elos Medtech report
Elos Medtech is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Elos Medtech and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.